290 related articles for article (PubMed ID: 33934516)
1. Establishment of a prognostic model of four genes in gastric cancer based on multiple data sets.
Zhou L; Li SH; Wu Y; Xin L
Cancer Med; 2021 May; 10(10):3309-3322. PubMed ID: 33934516
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
[TBL] [Abstract][Full Text] [Related]
3. A 16-mRNA signature optimizes recurrence-free survival prediction of Stages II and III gastric cancer.
Peng K; Chen E; Li W; Cheng X; Yu Y; Cui Y; Li Q; Wang Y; Xu X; Tang C; Gan L; Yu S; Liu T
J Cell Physiol; 2020 Jul; 235(7-8):5777-5786. PubMed ID: 32048287
[TBL] [Abstract][Full Text] [Related]
4. Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients.
Zhang C; Zhang CD; Ma MH; Dai DQ
World J Gastroenterol; 2018 Mar; 24(11):1206-1215. PubMed ID: 29568201
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer.
Cai WY; Dong ZN; Fu XT; Lin LY; Wang L; Ye GD; Luo QC; Chen YC
Theranostics; 2020; 10(19):8633-8647. PubMed ID: 32754268
[No Abstract] [Full Text] [Related]
6. Bioinformatics Analysis Reveals Prognostic Significance of the Macrophage Marker Gene Signature in Gastric Adenocarcinoma.
Li Z; Chen H; Chen Z; Xie L; Pan D
Front Biosci (Landmark Ed); 2024 May; 29(5):172. PubMed ID: 38812299
[TBL] [Abstract][Full Text] [Related]
7. Construction and Validation of a Novel Prognostic Signature for Intestinal Type of Gastric Cancer.
Zhang F; Maswikiti EP; Wei Y; Wu W; Li Y
Dis Markers; 2021; 2021():5567392. PubMed ID: 34422135
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive evaluation of FKBP10 expression and its prognostic potential in gastric cancer.
Liang L; Zhao K; Zhu JH; Chen G; Qin XG; Chen JQ
Oncol Rep; 2019 Aug; 42(2):615-628. PubMed ID: 31233188
[TBL] [Abstract][Full Text] [Related]
9. Genome-Scale Analysis Identified NID2, SPARC, and MFAP2 as Prognosis Markers of Overall Survival in Gastric Cancer.
Shan Z; Wang W; Tong Y; Zhang J
Med Sci Monit; 2021 Mar; 27():e929558. PubMed ID: 33758160
[TBL] [Abstract][Full Text] [Related]
10. Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer.
Lee IS; Sahu D; Hur H; Yook JH; Kim BS; Goel A
Gastric Cancer; 2021 May; 24(3):655-665. PubMed ID: 33523340
[TBL] [Abstract][Full Text] [Related]
11. Identification of ALDH3A2 as a novel prognostic biomarker in gastric adenocarcinoma using integrated bioinformatics analysis.
Yin Z; Wu D; Shi J; Wei X; Jin N; Lu X; Ren X
BMC Cancer; 2020 Nov; 20(1):1062. PubMed ID: 33148208
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of gastric cancer-associated gene signatures: Evidence based on a meta-analysis using integrated bioinformatics methods.
Wang J; Gao P; Song Y; Sun J; Chen X; Yu H; Wang Y; Wang Z
J Cell Mol Med; 2018 Nov; 22(11):5743-5747. PubMed ID: 30133128
[TBL] [Abstract][Full Text] [Related]
13. A prognostic 3-long noncoding RNA signature for patients with gastric cancer.
Cheng P
J Cell Biochem; 2018 Nov; 119(11):9261-9269. PubMed ID: 30074647
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel gene signature in patients without Helicobacter pylori infection gastric cancer.
Lv X; Zhao Y; Zhang L; Zhou S; Zhang B; Zhang Q; Jiang L; Li X; Wu H; Zhao L; Wei M; He M
J Cell Biochem; 2020 Feb; 121(2):1842-1854. PubMed ID: 31633246
[TBL] [Abstract][Full Text] [Related]
15. Integrated bioinformatics analysis reveals novel key biomarkers and potential candidate small molecule drugs in gastric cancer.
Wu Q; Zhang B; Wang Z; Hu X; Sun Y; Xu R; Chen X; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Xue Q; Zhou YL
Pathol Res Pract; 2019 May; 215(5):1038-1048. PubMed ID: 30975489
[TBL] [Abstract][Full Text] [Related]
16. "3G" Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy.
An O; Song Y; Ke X; So JB; Sundar R; Yang H; Rha SY; Lee MH; Tay ST; Ong X; Tan ALK; Ng MCH; Tantoso E; Chen L; Tan P; Yong WP;
Cancer Res; 2021 May; 81(10):2788-2798. PubMed ID: 33558338
[TBL] [Abstract][Full Text] [Related]
17. Bioinformatics-Based Identification of Methylated-Differentially Expressed Genes and Related Pathways in Gastric Cancer.
Li H; Liu JW; Liu S; Yuan Y; Sun LP
Dig Dis Sci; 2017 Nov; 62(11):3029-3039. PubMed ID: 28914394
[TBL] [Abstract][Full Text] [Related]
18. Identification of Potential Biomarkers Associated with Prognosis in Gastric Cancer via Bioinformatics Analysis.
Li D; Yin Y; He M; Wang J
Med Sci Monit; 2021 Feb; 27():e929104. PubMed ID: 33582701
[TBL] [Abstract][Full Text] [Related]
19. Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer.
Ma B; Li Y; Ren Y
Cancer Med; 2020 Jan; 9(1):335-349. PubMed ID: 31743579
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
